Abstract
A 12-year-old female suffering fromosteogenesis imperfecta (OI) was treated with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) orally, 250 mg daily, for periods of 2 months, alternating with periods of 2 months of abstinence. Total duration of therapy was 1 year. Radiological and clinical improvement was striking. Furthermore, X-rays of the bones showed large, parallel radio-opaque striae, corresponding exactly to the periods of therapy. These were present in all metaphyses.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baron R, Gertner JM, Lang R, Vignery A (1983) Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 17:204
Boerema I (1941–1942) Über das Knochenwachstum. Acta Neerl Morph 4:365
Cremin B, Goodman H, Spranger J, Beighton P (1982) Wormian bones in osteogenesis imperfecta and other disorders. Skeletal Radiol 8:35
Gottesleben A (1930) Kalkringe im wachsenden Knochen. Röntgenpraxis 2:673
Hoekman K, Papapoulous SE, Peters ACB, Bijvoet OLM (1985) Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 61:952
Huaux JP, Devogelaer JP, Brasseur JP, Nagant de Deuxchaisnes C (1985) Effect of the diphosphonate APD on dual photon absorptiometry in involutional osteoporosis. In: Norman AW, Schaefer K, Grigoleit HG, Herrath DV (eds) Vitamin D, chemical, biochemical and clinical update. Walter de Gruyter, Berlin, p 998
Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, Esselinckx W, Devogelaer JP, Withofs H, Meersseman F, Malghem J, Maldague B (1982) Treatment of Paget's disease with the diphosphonate APD. A biological and radiological study. In: Donath A, Courvoisier B (eds) Symposium CEMO IV: Diphosphonates and bone. Editions Médecine et Hygiène, Genève, p 303
Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, Withofs H, Meersseman F (1979) Healing of vitamin D-deficient osteomalacia by the administration of 1,25-(OH)2D3. In: MacIntyre I, Szeltke M (eds) Molecular endocrinology. Elsevier/North-Holland Biomedical Press, Amsterdam, p 375
Nagant de Deuxchaisnes C, Devogelaer JP, Esselinckx W, Depresseux G, Rombouts-Lindemans C, Huaux JP (1983) Non-hormonal treatment of osteoporosis. Br Med J 286: 1648
Pierog SH, Fontana VS, Ferrara A (1969) Osteogenesis imperfecta: therapeutic challenge. N Y State J Med 69:310
Rich C, Ensinck J, Ivanovich P (1964) The effects of sodium fluoride on calcium metabolism of subjects with metabolic bone diseases. J Clin Invest 43:545
Rosenberg E, Lang R, Boisseau V, Rojanasathit S, Avioli LV (1977) Effect of long-term calcitonin therapy on the clinical course of osteogenesis imperfecta. J Clin Endocrinol Metab 44:346
Sillence D (1981) Osteogenesis imperfecta: an expanding panorama of variants. Clin Orthop 159:11
Ste-Marie LG, Charhon SA, Edouard C, Chapuy MC, Meunier PJ (1984) Iliac bone histomorphometry in adults and children with osteogenesis imperfecta. J Clin Pathol 37:1081
Zanzi I, Wallach S, Ellis KJ, Aloia JF, Atkins HL, Cohn SH (1976) Long-term treatment of osteogenesis imperfecta tarda in adults with salmon calcitonin and calcium. Curr Ther Res 19:189
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Devogelaer, J.P., Malghem, J., Maldague, B. et al. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16, 360–363 (1987). https://doi.org/10.1007/BF00350961
Issue Date:
DOI: https://doi.org/10.1007/BF00350961